Drug Type Proteolysis-targeting chimeras (PROTAC) |
Synonyms- |
Target |
Action degraders |
Mechanism CCND1 degraders(Cyclin D1 degraders), CDK4 degraders(Cyclin-dependent kinase 4 degraders), CDK6 degraders(Cyclin-dependent kinase 6 degraders) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC52H65N11O7S |
InChIKeyYEWRCNAQUTTYAY-ODJFMHKTSA-N |
CAS Registry- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Preclinical | United States | 30 Nov 2022 | |
Neoplasms | Preclinical | United States | 30 Nov 2022 |